The Functional Assessment of Cancer Therapy-Bone Marrow Transplant measures quality of life (QOL) in SCT patients. Prior reports found mixed results regarding QOL differences among autologous and allogeneic SCT patients. In addition, there is a paucity of literature examining differences in QOL patterns over time between autologous and allogeneic patients. The present study examines differences in QOL between patients free of clinical depression undergoing autologous (n ¼ 41) and allogeneic (n ¼ 64) SCT during early stages of treatment. Despite clinical differences, autologous and allogeneic patients demonstrated similar changes in QOL. The exception was the Functional subscale which indicated worse QOL for allogeneic patients at discharge (F test ¼ 4.61, df ¼ 1, Po0.05); allogeneic patients (Mean ¼ 13.06, s.d. ¼ 5.36) indicated they were less able to function at work and were less accepting of their illness than autologous patients (Mean ¼ 16.02, s.d. ¼ 6.73). There was a significant main effect for time on nearly all QOL subscales (Po0.05) demonstrating decline during treatment and return to baseline by discharge; only the Social Well-Being scale did not significantly change over time. These results help to understand patients' response to SCT in the earliest stages and ultimately help identify patients at risk who could benefit from therapeutic interventions.
INTRODUCTION
As survival rates for patients undergoing stem cell transplant (SCT) have improved, there is an increased appreciation of the quality of life (QOL) of patients and their families. In the SCT population, QOL can provide important information to help guide treatment options and evaluate outcomes 1, 2 by examining it as a multidimensional construct that includes physical, functional, social, and psychological factors best reflected by patient self-report. 3, 4 Although an understanding of QOL in SCT began to emerge more than a decade ago, a variety of issues merit additional study. Andrykowski 1 for example suggested further exploration of factors that can help explain the variability seen in the QOL of SCT recipients, as well as understanding the temporal course of QOL through the treatment process. Despite efforts in the field to address these areas since that time, some specific issues have yet to be explored.
There has been a tendency with published reports to combine the findings from autologous and allogeneic transplant patients. However, these groups often have different clinical presentations and different treatments, recovery rates and mortality. [4] [5] [6] [7] [8] The limited studies of QOL in these separate populations have demonstrated inconsistent results, with some finding lower QOL in allogeneic patients, 8 whereas other studies have failed to find significant differences. 2, 9 The lack of information about the psychological well-being of patients at baseline also makes it difficult to assess the actual impact of SCT on individuals. Pre-transplant (baseline) physical and mental health functioning have been found to be strongly associated with QOL measures post-transplant. 10 Although patient samples may contain elevated rates of depression at baseline, 2, 11, 12 even as early as the initial SCT consultation, 13, 14 some studies have not formally screened for psychological distress. 9 Considering the significant association between depression and QOL, 15 it is possible that the course of QOL following SCT differs between individuals who are depressed at baseline compared with those who are not depressed. However, many studies to date tend to examine only post-SCT effects 8, 9, 16, 17 with less emphasis on pre-SCT psychosocial functioning. 18 In another study examining transplant recovery and long-term functioning over a course of 5 years, the impact of pre-SCT depression was assessed. 19 In this report, 319 adults who had a SCT for leukemia or lymphoma were assessed longitudinally. Twenty-two percent of the sample met criteria for clinical depression and 31% had at least mild depressive symptoms at some point during treatment or recovery. Pre-transplant levels of depression predicted lower levels of physical functioning at follow-up, while less satisfaction with social support before transplant predicted impaired recovery of physical and emotional functioning. Although this was a prospective study, its primary focus was on long-term recovery and the only assessments during treatment were conducted before transplant and 90 days later.
As evidenced in the aforementioned studies, assessments regarding QOL and well-being in SCT recipients typically focus on baseline or long term outcomes, but do not assess QOL during the early stages of treatment. However, if at risk patients can be identified early in treatment, intervention may be initiated to prevent a further decline in QOL.
The present study reports on QOL outcomes in a sample of SCT patients free of clinical depression before SCT and includes a 1 comparable number of autologous and allogeneic patients. We examine differences in QOL between patients undergoing autologous and allogeneic SCT across the early stages of treatment to determine if the type of SCT has a differential impact on the various dimensions of QOL. We hypothesized that there would be no differences in QOL at baseline, and that patients receiving allogeneic transplants would have significantly lower QOL scores compared with autologous patients at reinfusion and discharge. We also report on QOL pre-and post-SCT, and compare patients across three time points (baseline, reinfusion, and discharge), to identify which dimensions of QOL are most impacted and at which point in time for both the entire group and within each group (autologous or allogeneic). We predicted scores for all the domains of QOL would decline significantly between baseline and reinfusion, but would increase significantly between reinfusion and discharge.
PATIENTS AND METHODS

Participants/recruitment
Eligible participants were any SCT candidate 18 years or older seen at our institution from 2004 to 2008. Participants were excluded if they were receiving any psychotropic medications (with the exception of lorazepam prescribed for nausea), were being treated for depression, or had a history of major mental illness. In addition, study entry required that no evidence of severe depression was seen on pre-admission testing as measured by the Beck Depression Inventory-II (BDI-II) described below. All nondepressed eligible patients were also enrolled in a randomized study that explored the utility of a 12-week course of sertraline for the prevention of depression and behavioral comorbidities with SCT. As no differences were seen for depression scores during the time frame for the current analysis, the data from the active and placebo groups were combined. 20 We also verified that the placebo and treatment groups showed no significant demographic differences or differences across time points for the measures used in this study. During the length of this study (from 2004 to 2008) forty-nine patients met inclusion criteria for the study but declined participation. w 2 -and t-Test analyses showed no significant differences between those that declined to participate and those who completed the study in terms of age, gender, ethnicity, diagnosis, or type of transplant.
Procedure
All SCT patients were approached before admission by a psychologist and/or oncologist to provide informed consent for inclusion in a double-blind randomized clinical trial to evaluate the efficacy of sertraline in nondepressed SCT patients to prevent depression post transplant. A clinical interview by a licensed psychologist or supervised clinical psychology doctoral candidate took place to formally assess for pre-existing depression. The BDI-II, was administered and if the patient's total BDI-II score was greater than a cutoff of 20 points 21 a second interview by a nonstudy clinical psychologist or psychiatrist took place to document the degree of clinical depression. If the patient was determined not to be clinically depressed, the patient continued in the study. If the patient was determined to be clinically depressed, pharmacological treatment was offered, as well as psychotherapy off study. Once the initial assessment was completed, demographic and medical data for eligible patients were obtained through a chart review and baseline QOL was measured using the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) (described below).
Demographic, medical data and FACT-BMT scores from the following time points: baseline or T1, reinfusion (when SCT was received) or T2, and hospital discharge or T3 were analyzed for the current study. The median time at which the baseline assessment was conducted was week 0 (hospitalization), and it ranged from 4 weeks pre-hospital admission to the first week of admission before receiving the SCT. The median time for reinfusion or T2 assessment was within the week patient received the SCT, with a range between one and two weeks post-SCT. Discharge or T3 median time was 3 weeks post-SCT with a range from 2 to 8 weeks post SCT. The number of weeks at discharge varied based on the patient's status; 75% of the sample was discharged 4 weeks after reinfusion.
Assessment measures
Beck Depression Inventory-II (BDI-II). The BDI-II consists of 21 items designed to measure the severity of depressive symptoms based on the patient's report. Each item reflects a symptom of depression and respondents use a four-point Likert scale to indicate the degree to which they have experienced that symptom in the past two weeks. It yields an overall composite score with higher scores reflecting more severe depressive symptoms; 0-13 minimal depressive symptoms, 14-19 mild, 20-28 moderate, and 29-63 severe. The BDI-II has been shown to have good reliability with Cronbach's coefficient alpha ¼ 0.92 and has demonstrated high correlations with other measures of depression indicating both convergent and discriminant validity. 21 Functional Assessment of Cancer Treatment-Bone Marrow Transplant (FACT-BMT). The FACT-BMT consists of 27 items that yield a general score, the FACT-G, developed and validated by Cella et al., 22 and 23 items of the Bone Marrow Transplant Scale (BMTS) developed and validated by McQuellon et al. 2 The FACT-BMT was developed with the aim of assessing QOL in bone marrow transplant (BMT) patients. It contains subscales for Physical, Social/Family, Emotional, and Functional Well-Being (that is, the FACT-G), as well as a subscale for BMT specific concerns (yielding a BMTS score from 10 scored items). The Total FACT-BMT is obtained by adding the FACT-G and the BMTS scores. Each of the 50-items (Version 4 of the instrument) is rated on a five-point Likert scale from 0 (not at all) to 4 (very much) based on the patient's perception of his or her functioning over the previous 7 days. Higher scores indicate better QOL.
The FACT-G has well-established validity and reliability across a wide variety of patient groups, including breast cancer, 23 lung cancer, 24 and brain tumor 25 among others. Test-retest reliability for the FACT-G total score (Cronbach's alpha) has been estimated at 0.89, with Cronbach's alpha for individual subtests ranging from 0.65 to 0.82. 22 In a study of 182 BMT patients, 2 reported FACT-G total score test-retest reliability (Cronbach's alpha) was 0.88, with FACT-G subtest reliability coefficients ranging from 0.62 to 0.84, a BMTS coefficient of 0.63, and an overall FACT-BMT total coefficient of 0.90.
Statistical analyasis
Previous research 2 examining baseline to discharge changes in QOL found effect sizes (Cohen's d) of 0.37 for the overall FACT-BMT score, 0.27 for the FACT-G total score, and 0.57 for the BMT total score. On the basis of these findings an estimated effect size of 0.3 was used for a power analysis. As the effect size estimates 2 were based on repeated-measures t-Tests for variables at baseline and discharge, and similar analyses were planned for the present study, power analysis was calculated for repeated measures t-Tests using G*Power software. 26 To achieve 80% power at alpha ¼ 0.05 for an effect size of 0.3 a total sample of 90 patients would be needed. As such, the present sample is believed to have an adequate number to detect meaningful differences between groups over time.
t-Tests and w 2 -squares were performed to compare the allogeneic and autologous group on demographic and clinical variables. A series of 2 Â 3 (type of transplant Â time points) mixed-model analysis of variance (ANOVA) analyses with time as a repeated measure were conducted for each of the FACT subscale scores for the 105 patients that were assessed at all three time points. Post-hoc pairwise comparisons with Bonferroni correction were performed for each subscale across the three time points (baseline, reinfusion, and discharge).
RESULTS
The sample for the current study consisted of 123 cancer patients who underwent an autologous (n ¼ 48) or allogeneic (n ¼ 75) SCT. Of the original 123 patients, 105 completed assessment at all three time points in the study (that is, baseline, reinfusion, and discharge). Three patients died early owing to septic shock, three withdrew consent for unspecified personal reasons, six discontinued owing to medical complications, four were withdrawn owing to development of clinical depression, and two did not complete testing due to unspecified reasons. t-Test and w 2 -square analyses revealed no significant differences between those who completed the study and those who withdrew on baseline demographics, QOL scores or clinical variables. As expected, the length of hospitalization was longer for those who withdrew (t ¼ 4.90, df ¼ 121, Po0.001).
Of the 105 patients that completed the study t-Test and w 2 -squares also revealed no significant differences between the allogeneic and autologous groups for age, education, gender, marital status, ethnicity, employment status, or study drug (Table 1) . Expected group differences were noted in length of hospitalization (t ¼
No significant interaction between type of transplant (autologous or allogeneic) and time (baseline, reinfusion and discharge) was found for any of the FACT-BMT subscales (that is, Physical, Social, Emotional and Functional Well-Being), FACT-G, BMTS or total FACT-BMT. Refer to Table 2 for detailed information. In addition, no main effect was found for type of transplant for any of the subscales with the exception of Functional Well-Being (F ¼ 4.61, df ¼ 1, po0.05) .
Post-hoc independent t-Tests indicated that for the Functional Well-Being subscale significant mean differences were found for time 3 
Independent t-Tests were used to examine the seven items that composed the Functional Well-Being subscale at the time of discharge. Group differences (autologous versus allogeneic) were found on the following items: 'I am able to work' (t ¼ 2.56, P ¼ 0.013), 'my work (include work from home) is fulfilling' (t ¼ 2.30, P ¼ 0.023) and 'I have accepted my illness'(t ¼ 2.40, P ¼ 0.018). Patients in the allogeneic group reported they were less able to do their work, that they found their work less fulfilling, and that they only 'somewhat' accepted their illness. Furthermore, there was a significant correlation between the number of days of neutropenia and the Functional Well-Being scale (r ¼ À 0.277, Po0.01), such that patients with more days of neutropenia were more likely to report decreased functional well-being. There were no other significant correlations between any of the QOL measures with medical variables, including acute or chronic GVHD, diagnosis, length of hospitalization, or treatment regimen (for example, TBI, BU, BCNU-based, or others).
Main effects for time were significant for all the subscales with the exception of Social Well-Being. Mean scores by group across each of the three time points for all subscales are reported in Table 3 and subscale means over time are graphed in Figure 1 . Post-hoc pairwise comparisons with Bonferroni correction were performed between each of the time points for each subscale and are presented in Table 4 .
For the BMTS, scores declined significantly between baseline and reinfusion, but did not improve by discharge. Owing to the heterogeneous nature of the BMTS items a series of repeated measures ANOVAs were performed for each of the 10 scored items across the 3 time points in order to explore significant differences in patients' individual item responses. Patterns of item responses across time points are presented in Table 5 .
DISCUSSION
The present study explored the effects of SCT on patients' QOL during the early treatment and recovery phases, that is, pre-SCT through discharge from the acute care setting, in a sample of 105 autologous and allogeneic transplant patients who were free of clinical depression before their SCT. Consistent with the literature, the autologous and allogeneic transplant patients did not differ in QOL measures before SCT. Contrary to our expectations, no significant interactions between the two types of transplants and changes over time were seen in QOL dimensions as measured by the FACT-BMT subscales, with the exception of the Functional Well-Being subscale. In other words, despite the fact that individuals undergoing allogeneic transplants face greater risks and longer treatment courses, in our sample their response during the early stages of treatment is consistent with those undergoing autologous treatment.
We found that in non-depressed SCT patients, overall QOL as measured by the FACT-BMT declines during the acute treatment phase (from baseline to reinfusion) and returns to near baseline levels by discharge. However, not all aspects of QOL followed this pattern. For example, on the Emotional Well-Being subscale, Note: **Po0.01.
Early quality of life outcomes in SCT patients CM Garcia et al patients' scores did not differ from baseline to reinfusion, but did significantly improve by discharge. When patients are admitted for a SCT, they may naturally feel nervous and worried about the upcoming treatment and experience considerable uncertainty as to how they are going to cope or how successful the transplant will be. Thus, at the time of discharge much of this anxiety has diminished as patients have already experienced the transplant, answering some of their initial uncertainties. 27 However, it should be noted that patients in our study were not clinically depressed before SCT and therefore this finding may not hold true for patients with increased levels of depression or distress pre-SCT.
We recommend that physicians and members of the treatment team be alert for patients in which this improvement is not seen, as it may be an early indicator for depression.
The Functional Well-Being was the only subscale on which the groups significantly differed. Allogeneic transplant patients had significantly lower functional levels than autologous patients at discharge. When items of this subscale were analyzed, group differences were found with allogeneic transplant patients reporting that they were less able to perform their work, found their work less fulfilling, and only 'somewhat' accepted their illness. Two factors may account for these differences. First, allogeneic patients tend to have a longer recovery period, a longer hospitalization, and a higher risk for medical complications. [5] [6] [7] [8] Consistent with these reports, allogeneic patients in our study did have a longer hospitalization. Consequently, allogeneic patients may find it more difficult to accept and adapt to their illness, and their ability to return to work may be delayed. A second factor that may account for the difference between work-related responses is that 48% of the allogeneic group versus 32% of the autologous group were employed before treatment. In our study, the Social Well-Being subscale was the only one that did not change significantly across the early stages of the SCT process. This temporal stability speaks to the fact that patients perceived their level of support as the same regardless of the severity of their symptoms in other domains, at least in the early stages of treatment. Satisfaction with social support is a wellestablished protective factor and has been linked to lower levels of distress. 28, 29 Thus it is important for the staff to educate patient's loved ones and caregivers about this aspect of recovery and to help them maintain levels of adequate support throughout the SCT treatment and recovery process.
In interpreting the BMTS items, results showed that patients feel treatment is worse than they had anticipated and body image is of particular concern. These results seemed to suggest that improving patients' education regarding the side effects of treatment and its impact on physical functions and body image at the beginning of the treatment process may ease adjustment in the early stages of treatment.
This study sample was limited to individuals who were medically well enough, willing to participate and were without clinically significant mental health issues before SCT, creating a selection bias. In addition, ethnic diversity was limited in the sample. As such, results cannot be generalized outside this population. Although the sample size was adequate to address the research questions, it was not sufficient for more in depth analysis of a host of comorbid medical conditions and issues that might have an impact on the perception of QOL and treatment outcomes in general. Another limitation is that the study examined QOL only in the early stages of treatment and recovery and therefore does not reflect long-term trends.
Despite the consensus in psycho-oncology for the need to perform early psychosocial screening and interventions in order to prevent long-term distress in cancer patients, 30, 31 surveys have indicated that routine assessment and intervention on distress are rarely followed. 31 By exploring the patterns of QOL in individuals free of clinical depression during the early but acute stages of the SCT, this study was able to show the patterns that the different dimensions of QOL followed from the moment patients are hospitalized pre-SCT to the moment they are discharged from the hospital. These results suggest that failure to see improvements in emotional status over the course of treatment or a lack of improvement in perceived physical functioning between reinfusion and discharge may warrant concerns, as these patterns differ from the normal course of recovery and could reflect maladaptive coping with treatment. Assessing and intervening at this early stage of treatment, may be most effective as patients can be more closely monitored and psychological support services may be more readily available. Future research to identify how specific patterns of recovery from SCT in the earliest stages of treatment relate to long-term health and functioning, and identifying effective interventions to alter these pattern could significantly improve outcomes. 
